Unyvero’s sample-to-answer platform provides rapid results for severe infectious diseases in hospitalized patients

Powerful multiplex PCR technology combined with the broadest range of microorganism and resistance targets sets the Unyvero System apart.

The Unyvero System consists of:
- **Lysator**: to lyse and process a variety of native samples
- **Cockpit**: to manage testing process, display, store, and transmit results
- **Analyzer**: to perform DNA testing with random-access, multiplex PCR

A single test handles one patient sample, analyzes over 100 DNA analytes and delivers reliable results within just 4-5 hours

Unyvero is designed to expand with your growing needs

Applications for severe infections:
- Blood Culture – BCU
- Hospitalized Pneumonia – HPN
- Implant & Tissue Infection – ITI
- Intra-Abdominal Infection – IAI
- Urinary Tract Infection – UTI

Blood Culture

Leading the way to improve patient outcomes
In industrialized countries, sepsis is responsible for as many deaths as heart attacks.

- Sepsis is a major health issue and its recorded incidence is rising every year.
- Mortality rates can be as high as 50%.
- Every hour effective antibiotic treatment is delayed, sepsis mortality rate increases up to 8%.
- Early identification can help reduce morbidity and mortality, improve patient care and reduce healthcare costs.

Worldwide, someone dies of sepsis every 3-4 seconds.

Faster detection enables earlier optimization of therapy

The Unyvero BCU Application simultaneously identifies a large panel of bacteria, fungi and antibiotic resistance genes.

- Pathogen identification can take days using routine microbiology methods.
- Every hour effective antibiotic treatment is delayed.
- Early identification can help reduce morbidity and mortality, improving patient care and reducing healthcare costs.

Clinical evidence demonstrates the benefits provided by the Unyvero solution

- 96.8% Sensitivity
- 99.8% Specificity

Study 1

- Multicenter performance evaluation.
- Clinical laboratories from HDZ Bad Oeynhausen, UKE Hamburg and OWS Vienna.
- Study population: 46 patients.
- Age 1 month to 45 years.
- 23,000 to 29,000 deaths in Europe.
- 119 resistance genes detected.
- Reduced by 34 hours compared to identification results.
- Reduced by 11 hours compared to identification results.
- Reduced by 23 hours compared to full AST results.

Study 2

- Comparison with routine microbiology, University Hospital Essen, Germany.
- Spiked cultures:
  - 7/7 Spiked bacteria correctly identified.
  - 5/5 Resistance markers correctly identified (mecC, vanA and vanB).

Conclusion

- The Unyvero BCU Application is a useful tool for the rapid detection of pathogens and resistance markers directly from positive blood cultures.